Analyst firms · Needham · GMED
Needham GMED price target and rating history
Globus Medical Inc. (GMED) · Health Care
Needham rates Globus Medical Inc. (GMED) Buy with a $112 price target, as of its latest action on Jan 30, 2026. It has published 4 rating actions on GMED since August 2021, including 1 upgrade and 1 downgrade. Across 4 firms with a GMED price target in the last 12 months, the median target is $96. Needham's $112 is 17% above that.
- Current rating
- Buy
- Price target
- $112
- Median target, all firms
- $96
- Actions on GMED
- 4
Needham price target on GMED
Every Needham rating on GMED
- Jan 30, 2026
- Feb 10, 2023DowngradeNeedham downgrades to Hold from Buy
- Feb 18, 2022
- Aug 5, 2021
How other firms rate GMED
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| BMO Capital Markets | Market Perform | $78 | Nov 6, 2026 |
| UBS | Neutral | $82 | Jul 28, 2026 |
| Needham | Buy | $112 | Jan 30, 2026 |
| TD Cowen | Buy | $110 | Jan 27, 2026 |
Questions about Needham and GMED
- What is Needham's price target for GMED?
- Needham's latest stated price target for Globus Medical Inc. (GMED) is $112, from its action on Jan 30, 2026.
- What is Needham's rating on GMED?
- Needham rates GMED Buy, a bullish rating, as of Jan 30, 2026.
- When did Needham last change its view on GMED?
- On Jan 30, 2026, Needham upgrades to Buy from Hold, price target $112.
- How does Needham's GMED target compare with other analysts?
- Across 4 firms with a GMED price target in the last 12 months, the median target is $96. Needham's $112 is 17% above that.
More GMED rating histories
All Needham ratingsGMED news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.